Top Markets
Coin of the day
Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals, Inc.

ZYNE
Clasificación en acciones #26763
Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in... Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in the clinical development phase. Its primary objective is to create and advance medicinal transdermal cannabinoid treatments specifically for uncommon and scarcely encountered neuropsychiatric conditions. A key product in its pipeline is Zygel, a pharmaceutical-grade cannabidiol expertly crafted into a gel with enhanced skin penetration for topical application. Originally established as AllTranz, Inc., the company adopted its current name, Zynerba Pharmaceuticals, Inc., in August 2014. Founded in 2007, Zynerba Pharmaceuticals maintains its headquarters in Devon, Pennsylvania.
Precio por acción
$1.30
Última sincronización: 2023-10-13
Capitalización bursátil
$38.02M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Zynerba Pharmaceuticals, Inc. (ZYNE)

Categoría

Ratio P/B de Zynerba Pharmaceuticals, Inc. (ZYNE)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Zynerba Pharmaceuticals, Inc., el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de Zynerba Pharmaceuticals, Inc. desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras